AMI Asset Management Corp Has $49.10 Million Stock Position in Insulet Corporation $PODD

AMI Asset Management Corp lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 159,031 shares of the medical instruments supplier’s stock after selling 2,922 shares during the period. Insulet accounts for 2.7% of AMI Asset Management Corp’s holdings, making the stock its 13th biggest holding. AMI Asset Management Corp’s holdings in Insulet were worth $49,098,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Kozak & Associates Inc. bought a new stake in Insulet in the second quarter valued at approximately $32,000. Golden State Wealth Management LLC increased its position in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in Insulet during the 2nd quarter worth approximately $35,000. Osterweis Capital Management Inc. acquired a new stake in Insulet in the second quarter valued at approximately $51,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PODD. Royal Bank Of Canada raised their price target on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Rothschild & Co Redburn increased their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Canaccord Genuity Group lifted their target price on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. UBS Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. Finally, JPMorgan Chase & Co. raised their price objective on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $379.00.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $288.49 on Friday. The firm has a market capitalization of $20.29 billion, a PE ratio of 83.62, a P/E/G ratio of 2.03 and a beta of 1.37. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $314.27 and a two-hundred day moving average price of $312.95. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. Insulet’s revenue was up 29.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 EPS. Equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.